17 Multiple Myeloma Clinical Trials in Durham, NC (2026)

Q: How do I join a clinical trial in Durham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you.

Recruiting Multiple Myeloma Studies in Durham

NCT03276923Recruiting

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women...

Durham, NC1,000 participantsDuke University

View Study Details

NCT05730036Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had adv...

Durham, NCPHASE3410 participantsRegeneron Pharmaceuticals

View Study Details

NCT06351631Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

Durham, NCPHASE3400 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06365060Recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is o...

Durham, NC400 participantsTufts Medical Center

View Study Details

NCT02343042Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/re...

Durham, NCPHASE1300 participantsKaryopharm Therapeutics Inc

View Study Details

NCT06500884Recruiting

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preven...

Durham, NCPHASE2210 participantsJanssen Research & Development, LLC

View Study Details

NCT06722235Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...

Durham, NCPHASE3171 participantsTakeda

View Study Details

NCT05651932Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent...

Durham, NCPHASE1165 participantsK36 Therapeutics, Inc.

View Study Details

NCT06948318Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making i...

Durham, NCPHASE3150 participantsTakeda

View Study Details

NCT07115745Recruiting

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participan...

Durham, NCPHASE1125 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06747351Recruiting

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are ...

Durham, NCPHASE359 participantsTakeda

View Study Details

NCT05145400Recruiting

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The stu...

Durham, NCPHASE250 participantsUNC Lineberger Comprehensive Cancer Center

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Durham, NCPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT02310867Recruiting

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had l...

Durham, NCPHASE250 participantsLinda Cendales

View Study Details

NCT04925375Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promis...

Durham, NCPHASE238 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT06822972Recruiting

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM...

Durham, NCPHASE227 participantsDuke University

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Durham, NCPHASE120 participantsAdaptimmune

View Study Details

About Multiple Myeloma Clinical Trials in Durham

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 17 multiple myeloma clinical trials recruiting participants in Durham, NC. These studies are seeking a combined 3,625 participants. Research is being sponsored by Duke University, Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Durham — FAQ

Are there multiple myeloma clinical trials in Durham?

Yes, there are 17 multiple myeloma clinical trials currently recruiting in Durham, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Durham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you about next steps.

Are clinical trials in Durham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Durham studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 17 active trials in Durham are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 18, 2026 from ClinicalTrials.gov